{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:00:45Z","timestamp":1780891245996,"version":"3.54.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41390-020-01191-x","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T08:03:50Z","timestamp":1602317030000},"page":"1641-1649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models"],"prefix":"10.1038","volume":"89","author":[{"given":"Kathleen","family":"Marulanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick D.","family":"Tsihlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-4205","authenticated-orcid":false,"given":"Melina R.","family":"Kibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"1191_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.yapd.2018.05.001","volume":"65","author":"M Dingeldein","year":"2018","unstructured":"Dingeldein, M. Congenital diaphragmatic hernia: management & outcomes. Adv. Pediatr. 65, 241\u2013247 (2018).","journal-title":"Adv. Pediatr."},{"key":"1191_CR2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.sempedsurg.2017.04.008","volume":"26","author":"MT Harting","year":"2017","unstructured":"Harting, M. T. Congenital diaphragmatic hernia-associated pulmonary hypertension. Semin Pediatr. Surg. 26, 147\u2013153 (2017).","journal-title":"Semin Pediatr. Surg."},{"key":"1191_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jpedsurg.2003.11.010","volume":"39","author":"PW Dillon","year":"2004","unstructured":"Dillon, P. W. et al. The relationship of pulmonary artery pressure and survival in congenital diaphragmatic hernia. J. Pediatr. Surg. 39, 307\u2013312 (2004).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S1047951109003965","volume":"19","author":"B Thebaud","year":"2009","unstructured":"Thebaud, B. & Tibboel, D. Pulmonary hypertension associated with congenital diaphragmatic hernia. Cardiol. Young-. 19, 49\u201353 (2009).","journal-title":"Cardiol. Young-."},{"key":"1191_CR5","first-page":"25","volume":"56","author":"Centers for Disease Control.","year":"2007","unstructured":"Centers for Disease Control. Prevention Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects-United States, 2003. MMWR Morb. Mortal. Wkly Rep. 56, 25\u201329 (2007).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1191_CR6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jpedsurg.2015.10.082","volume":"51","author":"MA Coughlin","year":"2016","unstructured":"Coughlin, M. A. et al. Prenatally diagnosed severe CDH: mortality and morbidity remain high. J. Pediatr. Surg. 51, 1091\u20131095 (2016).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jpedsurg.2010.09.047","volume":"46","author":"MV Raval","year":"2011","unstructured":"Raval, M. V., Wang, X., Reynolds, M. & Fischer, A. C. Costs of congenital diaphragmatic hernia repair in the United States-extracorporeal membrane oxygenation foots the bill. J. Pediatr. Surg. 46, 617\u2013624 (2011).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jpedsurg.2016.02.005","volume":"51","author":"KP Lally","year":"2016","unstructured":"Lally, K. P. Congenital diaphragmatic hernia - the past 25 (or so) years. J. Pediatr. Surg. 51, 695\u2013698 (2016).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41390-019-0335-6","volume":"85","author":"S Perveen","year":"2019","unstructured":"Perveen, S. et al. MIF inhibition enhances pulmonary angiogenesis and lung development in congenital diaphragmatic hernia. Pediatr. Res. 85, 711\u2013718 (2019).","journal-title":"Pediatr. Res."},{"key":"1191_CR10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0002-9440(10)65000-6","volume":"156","author":"R Keijzer","year":"2000","unstructured":"Keijzer, R. et al. Dual-hit hypothesis explains pulmonary hypoplasia in the nitrofen model of congenital diaphragmatic hernia. Am. J. Pathol. 156, 1299\u20131306 (2000).","journal-title":"Am. J. Pathol."},{"key":"1191_CR11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s003830050429","volume":"14","author":"Y Taira","year":"1998","unstructured":"Taira, Y., Yamataka, T., Miyazaki, E. & Puri, P. Comparison of the pulmonary vasculature in newborns and stillborns with congenital diaphragmatic hernia. Pediatr. Surg. Int. 14, 30\u201335 (1998).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.yexmp.2012.09.010","volume":"94","author":"I Sluiter","year":"2013","unstructured":"Sluiter, I. et al. Premature differentiation of vascular smooth muscle cells in human congenital diaphragmatic hernia. Exp. Mol. Pathol. 94, 195\u2013202 (2013).","journal-title":"Exp. Mol. Pathol."},{"key":"1191_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00383-005-1593-4","volume":"22","author":"A Mortell","year":"2006","unstructured":"Mortell, A., Montedonico, S. & Puri, P. Animal models in pediatric surgery. Pediatr. Surg. Int. 22, 111\u2013128 (2006).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00383-008-2140-x","volume":"24","author":"S Montedonico","year":"2008","unstructured":"Montedonico, S., Nakazawa, N. & Puri, P. Congenital diaphragmatic hernia and retinoids: searching for an etiology. Pediatr. Surg. Int. 24, 755\u2013761 (2008).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41390-019-0345-4","volume":"85","author":"L Montalva","year":"2019","unstructured":"Montalva, L., Antounians, L. & Zani, A. Pulmonary hypertension secondary to congenital diaphragmatic hernia: factors and pathways involved in pulmonary vascular remodeling. Pediatr. Res. 85, 754\u2013768 (2019).","journal-title":"Pediatr. Res."},{"key":"1191_CR16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.siny.2014.09.008","volume":"19","author":"M Pierro","year":"2014","unstructured":"Pierro, M. & Thebaud, B. Understanding and treating pulmonary hypertension in congenital diaphragmatic hernia. Semin. Fetal Neonatal Med. 19, 357\u2013363 (2014).","journal-title":"Semin. Fetal Neonatal Med."},{"key":"1191_CR17","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1161\/CIRCULATIONAHA.105.541524","volume":"112","author":"B Th\u00e9baud","year":"2005","unstructured":"Th\u00e9baud, B. et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: Evidence that angiogenesis participates in alveolarization. Circulation 112, 2477\u20132486 (2005).","journal-title":"Circulation"},{"key":"1191_CR18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s003830100625","volume":"18","author":"T Oue","year":"2002","unstructured":"Oue, T. et al. Increased vascular endothelial growth factor peptide and gene expression in hypoplastic lung in nitrofen induced congenital diaphragmatic hernia in rats. Pediatr. Surg. Int. 18, 221\u2013226 (2002).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR19","doi-asserted-by":"crossref","first-page":"e0161334","DOI":"10.1371\/journal.pone.0161334","volume":"11","author":"S Umeda","year":"2016","unstructured":"Umeda, S. et al. Enhanced pulmonary vascular and alveolar development via prenatal administration of a slow-release synthetic prostacyclin agonist in rat fetal lung hypoplasia. PLoS ONE 11, e0161334 (2016).","journal-title":"PLoS ONE"},{"key":"1191_CR20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1203\/01.PDR.0000163614.20031.C5","volume":"58","author":"A Hara","year":"2005","unstructured":"Hara, A., Chapin, C. J., Ertsey, R. & Kitterman, J. A. Changes in fetal lung distension alter expression of vascular endothelial growth factor and its isoforms in developing rat lung. Pediatr. Res. 58, 30\u201337 (2005).","journal-title":"Pediatr. Res."},{"key":"1191_CR21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jpedsurg.2009.09.023","volume":"45","author":"CM Burgos","year":"2010","unstructured":"Burgos, C. M. et al. Gene expression analysis in hypoplastic lungs in the nitrofen model of congenital diaphragmatic hernia. J. Pediatr. Surg. 45, 1445\u20131454 (2010).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR22","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1161\/CIRCULATIONAHA.108.845909","volume":"123","author":"C Luong","year":"2011","unstructured":"Luong, C. et al. Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia. Circulation 123, 2120\u20132131 (2011).","journal-title":"Circulation"},{"key":"1191_CR23","doi-asserted-by":"crossref","first-page":"L672","DOI":"10.1152\/ajplung.00345.2014","volume":"308","author":"M Makanga","year":"2015","unstructured":"Makanga, M. et al. Prevention of pulmonary hypoplasia and pulmonary vascular remodeling by antenatal simvastatin treatment in nitrofen-induced congenital diaphragmatic hernia. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L672\u2013L682 (2015).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000484087","volume":"55","author":"S Zhaorigetu","year":"2018","unstructured":"Zhaorigetu, S. et al. Perturbations in endothelial dysfunction-associated pathways in the nitrofen-induced congenital diaphragmatic hernia model. J. Vasc. Res. 55, 26\u201334 (2018).","journal-title":"J. Vasc. Res."},{"key":"1191_CR25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0022-3468(96)90076-7","volume":"31","author":"HL Karamanoukian","year":"1996","unstructured":"Karamanoukian, H. L. et al. Decreased pulmonary nitric oxide synthase activity in the rat model of congenital diaphragmatic hernia. J. Pediatr. Surg. 31, 1016\u20131019 (1996).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR26","doi-asserted-by":"crossref","first-page":"L276","DOI":"10.1152\/ajplung.00392.2017","volume":"315","author":"DS Mous","year":"2018","unstructured":"Mous, D. S. et al. Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag\u2019s active compound, at the pseudoglandular stage improves lung vasculature. Am. J. Physiol. Lung Cell Mol. Physiol. 315, L276\u2013L285 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdrb.21117","volume":"101","author":"A Hofmann","year":"2014","unstructured":"Hofmann, A. et al. Imbalance of caveolin-1 and eNOS expression in the pulmonary vasculature of experimental diaphragmatic hernia. Birth Defects Res. B Dev. Reprod. Toxicol. 101, 341\u2013346 (2014).","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"1191_CR28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/CBB:44:1:147","volume":"44","author":"SMK Shehata","year":"2006","unstructured":"Shehata, S. M. K., Sharma, H. S., Mooi, W. J. & Tibboel, D. Pulmonary hypertension in human newborns with congenital diaphragmatic hernia is associated with decreased vascular expression of nitric-oxide synthase. Cell Biochem. Biophys. 44, 147\u2013155 (2006).","journal-title":"Cell Biochem. Biophys."},{"key":"1191_CR29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.yexmp.2010.11.003","volume":"90","author":"BG Sood","year":"2011","unstructured":"Sood, B. G. et al. Expression of eNOS in the lungs of neonates with pulmonary hypertension. Exp. Mol. Pathol. 90, 9\u201312 (2011).","journal-title":"Exp. Mol. Pathol."},{"key":"1191_CR30","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jpedsurg.2005.07.004","volume":"40","author":"Z Vukcevic","year":"2005","unstructured":"Vukcevic, Z., Coppola, C. P., Hults, C. & Gosche, J. R. Nitrovasodilator responses in pulmonary arterioles from rats with nitrofen-induced congenital diaphragmatic hernia. J. Pediatr. Surg. 40, 1706\u20131711 (2005).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1006\/jsre.1998.5382","volume":"79","author":"WS Scott","year":"1998","unstructured":"Scott, W. S. & Nakayama, D. K. Sustained nitric oxide exposure decreases soluble guanylate cyclase mRNA and enzyme activity in pulmonary artery smooth muscle. J. Surg. Res. 79, 66\u201370 (1998).","journal-title":"J. Surg. Res."},{"key":"1191_CR32","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie, N. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894\u20132903 (2009).","journal-title":"Circulation"},{"key":"1191_CR33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jpeds.2008.09.021","volume":"154","author":"PM Mourani","year":"2009","unstructured":"Mourani, P. M., Sontag, M. K., Ivy, D. D. & Abman, S. H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J. Pediatr. 154, 379\u2013384, 384 e371\u2013372 (2009).","journal-title":"J. Pediatr."},{"key":"1191_CR34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpeds.2018.09.067","volume":"205","author":"JL Cohen","year":"2019","unstructured":"Cohen, J. L. et al. Sildenafil use in children with pulmonary hypertension. J. Pediatr. 205, 29\u201334 e21 (2019).","journal-title":"J. Pediatr."},{"key":"1191_CR35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1542\/peds.2005-0523","volume":"117","author":"H Baquero","year":"2006","unstructured":"Baquero, H. et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117, 1077\u20131083 (2006).","journal-title":"Pediatrics"},{"key":"1191_CR36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ppul.23935","volume":"53","author":"F Kipfmueller","year":"2018","unstructured":"Kipfmueller, F. et al. Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia. Pediatr. Pulmonol. 53, 452\u2013460 (2018).","journal-title":"Pediatr. Pulmonol."},{"key":"1191_CR37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-0033-1357757","volume":"25","author":"A Bialkowski","year":"2015","unstructured":"Bialkowski, A., Moenkemeyer, F. & Patel, N. Intravenous sildenafil in the management of pulmonary hypertension associated with congenital diaphragmatic hernia. Eur. J. Pediatr. Surg. 25, 171\u2013176 (2015).","journal-title":"Eur. J. Pediatr. Surg."},{"key":"1191_CR38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpedsurg.2013.09.024","volume":"49","author":"EH Shue","year":"2014","unstructured":"Shue, E. H. et al. Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia. J. Pediatr. Surg. 49, 39\u201345 (2014).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000097125","volume":"91","author":"S Noori","year":"2007","unstructured":"Noori, S. et al. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 91, 92\u2013100 (2007).","journal-title":"Neonatology"},{"key":"1191_CR40","doi-asserted-by":"crossref","first-page":"L734","DOI":"10.1152\/ajplung.00180.2016","volume":"311","author":"DS Mous","year":"2016","unstructured":"Mous, D. S. et al. Clinically relevant timing of antenatal sildenafil treatment reduces pulmonary vascular remodeling in congenital diaphragmatic hernia. Am. J. Physiol. Lung Cell Mol. Physiol. 311, L734\u2013L742 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12519-014-0512-y","volume":"10","author":"L Lemus-Varela Mde","year":"2014","unstructured":"Lemus-Varela Mde, L. et al. Antenatal use of bosentan and\/or sildenafil attenuates pulmonary features in rats with congenital diaphragmatic hernia. World J. Pediatr. 10, 354\u2013359 (2014).","journal-title":"World J. Pediatr."},{"key":"1191_CR42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000358226","volume":"106","author":"J Kattan","year":"2014","unstructured":"Kattan, J., C\u00e9spedes, C., Gonz\u00e1lez, A. & Vio, C. P. Sildenafil stimulates and dexamethasone inhibits pulmonary vascular development in congenital diaphragmatic hernia rat lungs. Neonatology 106, 74\u201380 (2014).","journal-title":"Neonatology"},{"key":"1191_CR43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/thoraxjnl-2015-207949","volume":"71","author":"FM Russo","year":"2016","unstructured":"Russo, F. M. et al. Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia. Thorax 71, 517\u2013525 (2016).","journal-title":"Thorax"},{"key":"1191_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2897-8","volume":"19","author":"FM Russo","year":"2018","unstructured":"Russo, F. M. et al. Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (SToP-PH): study protocol for a phase I\/IIb placenta transfer and safety study. Trials 19, 524 (2018).","journal-title":"Trials"},{"key":"1191_CR45","volume":"17","author":"A Pels","year":"2017","unstructured":"Pels, A. et al. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnency Childbirth 17, 440 (2017).","journal-title":"BMC Pregnency Childbirth"},{"key":"1191_CR46","doi-asserted-by":"crossref","first-page":"e20161450","DOI":"10.1542\/peds.2016-1450","volume":"139","author":"C Unegbu","year":"2017","unstructured":"Unegbu, C. et al. Pulmonary hypertension therapy and a systematic review of efficacy and safety of PDE-5 inhibitors. Pediatrics 139, e20161450 (2017).","journal-title":"Pediatrics"},{"key":"1191_CR47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/10641950802601278","volume":"28","author":"RA Samangaya","year":"2009","unstructured":"Samangaya, R. A. et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens. Pregnency 28, 369\u2013382 (2009).","journal-title":"Hypertens. Pregnency"},{"key":"1191_CR48","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1471-0528.2010.02879.x","volume":"118","author":"P von Dadelszen","year":"2011","unstructured":"von Dadelszen, P. et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. Bjog 118, 624\u2013628 (2011).","journal-title":"Bjog"},{"key":"1191_CR49","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2352-4642(19)30020-3","volume":"3","author":"A Sharp","year":"2019","unstructured":"Sharp, A. et al. Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. Lancet Child Adolesc. Health 3, e2\u2013e3 (2019).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1191_CR50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.sjbs.2010.12.007","volume":"18","author":"FM Abou-Tarboush","year":"2011","unstructured":"Abou-Tarboush, F. M., Abdel-Samad, M. F. & Al-Meteri, M. H. Developmental toxicity of orally administered sildenafil citrate (Viagra) in SWR\/J mice. Saudi J. Biol. Sci. 18, 135\u2013139 (2011).","journal-title":"Saudi J. Biol. Sci."},{"key":"1191_CR51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s12325-009-0064-z","volume":"26","author":"D Montani","year":"2009","unstructured":"Montani, D. et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv. Ther. 26, 813\u2013825 (2009).","journal-title":"Adv. Ther."},{"key":"1191_CR52","first-page":"7","volume":"66","author":"A Shiva","year":"2016","unstructured":"Shiva, A. et al. Oral tadalafil in children with pulmonary arterial hypertension. Drug Res. 66, 7\u201310 (2016).","journal-title":"Drug Res."},{"key":"1191_CR53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.earlhumdev.2014.10.007","volume":"91","author":"S Samiee-Zafarghandy","year":"2015","unstructured":"Samiee-Zafarghandy, S. et al. Safety of milrinone use in neonatal intensive care units. Early Hum. Dev. 91, 31\u201335 (2015).","journal-title":"Early Hum. Dev."},{"key":"1191_CR54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","volume":"410","author":"J-P Stasch","year":"2001","unstructured":"Stasch, J.-P. et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 410, 212\u2013215 (2001).","journal-title":"Nature"},{"key":"1191_CR55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000092518","volume":"90","author":"P Deruelle","year":"2006","unstructured":"Deruelle, P. et al. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol. Neonate. 90, 135\u2013144 (2006).","journal-title":"Biol. Neonate."},{"key":"1191_CR56","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/01.CIR.0000144469.01521.8A","volume":"110","author":"OV Evgenov","year":"2004","unstructured":"Evgenov, O. V. et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110, 2253\u20132259 (2004).","journal-title":"Circulation"},{"key":"1191_CR57","doi-asserted-by":"crossref","first-page":"L798","DOI":"10.1152\/ajplung.00119.2005","volume":"289","author":"P Deruelle","year":"2005","unstructured":"Deruelle, P., Grover, T. R. & Abman, S. H. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am. J. Physiol. Lung Cell Mol. Physiol. 289, L798\u2013L806 (2005).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR58","doi-asserted-by":"crossref","first-page":"L658","DOI":"10.1152\/ajplung.00178.2015","volume":"310","author":"A Vuckovic","year":"2016","unstructured":"Vuckovic, A. et al. Antenatal BAY 41-2272 reduces pulmonary hypertension in the rabbit model of congenital diaphragmatic hernia. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L658\u2013L669 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR59","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/jpet.106.108878","volume":"319","author":"A Pyriochou","year":"2006","unstructured":"Pyriochou, A. et al. Soluble guanylyl cyclase activation promotes angiogenesis. J. Pharm. Exp. Ther. 319, 663\u2013671 (2006).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1191_CR60","doi-asserted-by":"crossref","first-page":"H792","DOI":"10.1152\/ajpheart.00953.2010","volume":"300","author":"EA Pankey","year":"2011","unstructured":"Pankey, E. A. et al. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am. J. Physiol. Heart Circ. Physiol. 300, H792\u2013H802 (2011).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1191_CR61","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00383-014-3561-3","volume":"30","author":"JA Rojas-Moscoso","year":"2014","unstructured":"Rojas-Moscoso, J. A. et al. The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model. Pediatr. Surg. Int. 30, 1031\u20131036 (2014).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR62","doi-asserted-by":"crossref","first-page":"L214","DOI":"10.1152\/ajpcell.1992.262.1.C214","volume":"262","author":"SH Abman","year":"1992","unstructured":"Abman, S. H. & Stenmark, K. R. Changes in lung eicosanoid content during normal and abnormal transition in perinatal lambs. Am. J. Physiol. 262, L214\u2013L222 (1992).","journal-title":"Am. J. Physiol."},{"key":"1191_CR63","first-page":"197","volume":"1","author":"S Cassin","year":"1981","unstructured":"Cassin, S. et al. Effects of prostacyclin on the fetal pulmonary circulation. Pediatr. Pharm. 1, 197\u2013207 (1981).","journal-title":"Pediatr. Pharm."},{"key":"1191_CR64","volume":"18","author":"DS Mous","year":"2017","unstructured":"Mous, D. S. et al. Changes in vasoactive pathways in congenital diaphragmatic hernia associated pulmonary hypertension explain unresponsiveness to pharmacotherapy. Respir. Res. 18, 187 (2017).","journal-title":"Respir. Res."},{"key":"1191_CR65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpedsurg.2018.10.039","volume":"54","author":"KM Lawrence","year":"2019","unstructured":"Lawrence, K. M. et al. Use of prostaglandin E1 to treat pulmonary hypertension in congenital diaphragmatic hernia. J. Pediatr. Surg. 54, 55\u201359 (2019).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR66","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jpeds.2015.06.016","volume":"167","author":"E Olson","year":"2015","unstructured":"Olson, E. et al. Short-Term Treprostinil Use in Infants with Congenital Diaphragmatic Hernia following Repair. J. Pediatr. 167, 762\u2013764 (2015).","journal-title":"J. Pediatr."},{"key":"1191_CR67","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/rcmb.2005-0289OC","volume":"34","author":"FY Ali","year":"2006","unstructured":"Ali, F. Y. et al. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 34, 242\u2013246 (2006).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1191_CR68","doi-asserted-by":"crossref","unstructured":"Kuwano, K. et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetam ide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J. Pharmacol. Exp. Ther. 322, 1181\u20131188 (2007).","DOI":"10.1124\/jpet.107.124248"},{"key":"1191_CR69","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon, O. et al. Selexipag for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 373, 2522\u20132533 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1191_CR70","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1164\/rccm.200501-102OC","volume":"172","author":"M Kataoka","year":"2005","unstructured":"Kataoka, M. et al. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am. J. Respir. Crit. Care Med. 172, 1575\u20131580 (2005).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1164\/rccm.200703-349OC","volume":"177","author":"H Obata","year":"2008","unstructured":"Obata, H. et al. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 177, 195\u2013201 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","volume":"61","author":"N Gali\u00e9","year":"2004","unstructured":"Gali\u00e9, N., Manes, A. & Branzi, A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 61, 227\u2013237 (2004).","journal-title":"Cardiovasc. Res."},{"key":"1191_CR73","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3468(98)90367-0","volume":"33","author":"T Okazaki","year":"1998","unstructured":"Okazaki, T., Sharma, H. S., McCune, S. K. & Tibboel, D. Pulmonary vascular balance in congenital diaphragmatic hernia: enhanced endothelin-1 gene expression as a possible cause of pulmonary vasoconstriction. J. Pediatr. Surg. 33, 81\u201384 (1998).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR74","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ptr.5645","volume":"30","author":"S Hirako","year":"2016","unstructured":"Hirako, S. et al. Antenatal saireito (TJ-114) can improve pulmonary hypoplasia and pulmonary vascular remodeling in nitrofen-induced congenital diaphragmatic hernia. Phytother. Res. 30, 1474\u20131480 (2016).","journal-title":"Phytother. Res."},{"key":"1191_CR75","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1164\/rccm.200907-1126OC","volume":"182","author":"RL Keller","year":"2010","unstructured":"Keller, R. L. et al. Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity. Am. J. Respir. Crit. Care Med. 182, 555\u2013561 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR76","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1651-2227.2009.01386.x","volume":"98","author":"N Nakwan","year":"2009","unstructured":"Nakwan, N. et al. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 98, 1683\u20131685 (2009).","journal-title":"Acta Paediatr."},{"key":"1191_CR77","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811\u20132821 (2005).","journal-title":"J. Clin. Invest."},{"key":"1191_CR78","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","volume":"178","author":"F Perros","year":"2008","unstructured":"Perros, F. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 81\u201388 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493\u2013502 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1191_CR80","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","volume":"353","author":"HA Ghofrani","year":"2005","unstructured":"Ghofrani, H. A., Seeger, W. & Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353, 1412\u20131413 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1191_CR81","doi-asserted-by":"crossref","first-page":"L826","DOI":"10.1152\/ajplung.00199.2002","volume":"284","author":"V Balasubramaniam","year":"2003","unstructured":"Balasubramaniam, V. et al. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell Mol. Physiol. 284, L826\u2013L833 (2003).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR82","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani, H. A. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182, 1171\u20131177 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR83","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jpedsurg.2008.07.022","volume":"43","author":"B Frenckner","year":"2008","unstructured":"Frenckner, B., Broome, M., Lindstrom, M. & Radell, P. Platelet-derived growth factor inhibition-a new treatment of pulmonary hypertension in congenital diaphragmatic hernia? J. Pediatr. Surg. 43, 1928\u20131931 (2008).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR84","doi-asserted-by":"crossref","first-page":"L1159","DOI":"10.1152\/ajplung.00325.2010","volume":"302","author":"YT Chang","year":"2012","unstructured":"Chang, Y. T. et al. Antenatal imatinib treatment reduces pulmonary vascular remodeling in a rat model of congenital diaphragmatic hernia. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L1159\u2013L1166 (2012).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR85","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.biocel.2007.05.011","volume":"39","author":"R Garcia-Olivas","year":"2007","unstructured":"Garcia-Olivas, R., Vilaro, S., Reina, M. & Castel, S. PDGF-stimulated cell proliferation and migration of human arterial smooth muscle cells. Colocalization of PDGF isoforms with glycosaminoglycans. Int J. Biochem. Cell Biol. 39, 1915\u20131929 (2007).","journal-title":"Int J. Biochem. Cell Biol."},{"key":"1191_CR86","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.RES.0000182903.16652.d7","volume":"97","author":"A Armulik","year":"2005","unstructured":"Armulik, A., Abramsson, A. & Betsholtz, C. Endothelial\/pericyte interactions. Circ. Res. 97, 512\u2013523 (2005).","journal-title":"Circ. Res."},{"key":"1191_CR87","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jpedsurg.2017.12.002","volume":"53","author":"CM Burgos","year":"2018","unstructured":"Burgos, C. M. et al. Lung function and pulmonary artery blood flow following prenatal maternal retinoic acid and imatinib in the nitrofen model of congenital diaphragmatic hernia. J. Pediatr. Surg. 53, 1681\u20131687 (2018).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR88","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","volume":"43","author":"D Mattei","year":"2009","unstructured":"Mattei, D. et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 43, 967\u2013968 (2009).","journal-title":"Bone Marrow Transplant."},{"key":"1191_CR89","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2466-11-30","volume":"11","author":"JK Hennigs","year":"2011","unstructured":"Hennigs, J. K. et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm. Med. 11, 30 (2011).","journal-title":"BMC Pulm. Med."},{"key":"1191_CR90","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","volume":"118","author":"G Hansmann","year":"2008","unstructured":"Hansmann, G. et al. An antiproliferative BMP-2\/PPARgamma\/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Investig. 118, 1846\u20131857 (2008).","journal-title":"J. Clin. Investig."},{"key":"1191_CR91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1165\/rcmb.2019-0226PS","volume":"62","author":"G Hansmann","year":"2019","unstructured":"Hansmann, G., Calvier, L., Risbano, M. G. & Chan, S. Y. Activation of the metabolic master regulator PPAR\u03b3: a potential pioneering therapy for pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 62, 143\u2013156 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1191_CR92","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","volume":"53","author":"M Humbert","year":"2019","unstructured":"Humbert, M. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 53, 1801887 (2019).","journal-title":"Eur. Respir. J."},{"key":"1191_CR93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-10-6","volume":"10","author":"L Savale","year":"2009","unstructured":"Savale, L. et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 10, 6 (2009).","journal-title":"Respir. Res."},{"key":"1191_CR94","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","volume":"104","author":"MK Steiner","year":"2009","unstructured":"Steiner, M. K. et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104, 236\u2013244 (2009).","journal-title":"Circ. Res."},{"key":"1191_CR95","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1440-1843.2006.00821.x","volume":"11","author":"T Itoh","year":"2006","unstructured":"Itoh, T. et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 11, 158\u2013163 (2006).","journal-title":"Respirology"},{"key":"1191_CR96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00383-006-1858-6","volume":"23","author":"M Okawada","year":"2007","unstructured":"Okawada, M. et al. Serum monocyte chemotactic protein-1 levels in congenital diaphragmatic hernia. Pediatr. Surg. Int. 23, 487\u2013491 (2007).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR97","doi-asserted-by":"crossref","first-page":"e0206975","DOI":"10.1371\/journal.pone.0206975","volume":"13","author":"JH Gosemann","year":"2018","unstructured":"Gosemann, J. H. et al. Prenatal treatment with rosiglitazone attenuates vascular remodeling and pulmonary monocyte influx in experimental congenital diaphragmatic hernia. PLoS ONE 13, e0206975 (2018).","journal-title":"PLoS ONE"},{"key":"1191_CR98","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","volume":"151","author":"M Humbert","year":"1995","unstructured":"Humbert, M. et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151, 1628\u20131631 (1995).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR99","doi-asserted-by":"crossref","first-page":"L229","DOI":"10.1152\/ajplung.00238.2014","volume":"308","author":"SC Pugliese","year":"2015","unstructured":"Pugliese, S. C. et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L229\u2013L252 (2015).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR100","first-page":"14","volume":"2018","author":"M Ahmed","year":"2018","unstructured":"Ahmed, M. & Miller, E. Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension. Glob. Cardiol. Sci. Pract. 2018, 14 (2018).","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"1191_CR101","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/pr.2013.98","volume":"74","author":"S Fleck","year":"2013","unstructured":"Fleck, S. et al. Fetal production of growth factors and inflammatory mediators predicts pulmonary hypertension in congenital diaphragmatic hernia. Pediatr. Res. 74, 290\u2013298 (2013).","journal-title":"Pediatr. Res."},{"key":"1191_CR102","doi-asserted-by":"crossref","first-page":"L1473","DOI":"10.1152\/ajplung.00197.2006","volume":"292","author":"M Hagen","year":"2007","unstructured":"Hagen, M. et al. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1473\u2013L1479 (2007).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR103","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.RES.0000073585.50092.14","volume":"92","author":"S Ameshima","year":"2003","unstructured":"Ameshima, S. et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 92, 1162\u20131169 (2003).","journal-title":"Circ. Res."},{"key":"1191_CR104","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1203\/00006450-199911000-00023","volume":"46","author":"H Shima","year":"1999","unstructured":"Shima, H. et al. Antenatal dexamethasone suppresses tumor necrosis factor- expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats. Pediatr. Res. 46, 633\u2013637 (1999).","journal-title":"Pediatr. Res."},{"key":"1191_CR105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00383-012-3209-0","volume":"29","author":"JH Gosemann","year":"2013","unstructured":"Gosemann, J. H. et al. Increased activation of NADPH oxidase 4 in the pulmonary vasculature in experimental diaphragmatic hernia. Pediatr. Surg. Int. 29, 3\u20138 (2013).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR106","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/79510","volume":"6","author":"Y Kureishi","year":"2000","unstructured":"Kureishi, Y. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004\u20131010 (2000).","journal-title":"Nat. Med."},{"key":"1191_CR107","doi-asserted-by":"crossref","first-page":"L1105","DOI":"10.1152\/ajplung.00411.2006","volume":"292","author":"RE Girgis","year":"2007","unstructured":"Girgis, R. E. et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1105\u2013L1110 (2007).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR108","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.RES.0000196564.18314.23","volume":"97","author":"Y Rikitake","year":"2005","unstructured":"Rikitake, Y. & Liao, J. K. Rho GTPases, statins, and nitric oxide. Circ. Res. 97, 1232\u20131235 (2005).","journal-title":"Circ. Res."},{"key":"1191_CR109","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjp.0706114","volume":"144","author":"F Mraiche","year":"2005","unstructured":"Mraiche, F., Cena, J., Das, D. & Vollrath, B. Effects of statins on vascular function of endothelin-1. Br. J. Pharmacol. 144, 715\u2013726 (2005).","journal-title":"Br. J. Pharmacol."},{"key":"1191_CR110","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.200203-268OC","volume":"166","author":"T Nishimura","year":"2002","unstructured":"Nishimura, T. et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 166, 1403\u20131408 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1191_CR111","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000087592.47401.37","volume":"108","author":"T Nishimura","year":"2003","unstructured":"Nishimura, T. et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108, 1640\u20131645 (2003).","journal-title":"Circulation"},{"key":"1191_CR112","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/bdra.20181","volume":"73","author":"PS Pollack","year":"2005","unstructured":"Pollack, P. S. et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res. A Clin. Mol. Teratol. 73, 888\u2013896 (2005).","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"1191_CR113","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/01902148.2013.816803","volume":"39","author":"AC Inamdar","year":"2013","unstructured":"Inamdar, A. C. & Inamdar, A. A. Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp. Lung Res. 39, 315\u2013327 (2013).","journal-title":"Exp. Lung Res."},{"key":"1191_CR114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/stem.548","volume":"29","author":"OD Liang","year":"2011","unstructured":"Liang, O. D. et al. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells 29, 99\u2013107 (2011).","journal-title":"Stem Cells"},{"key":"1191_CR115","doi-asserted-by":"crossref","first-page":"H1120","DOI":"10.1152\/ajpheart.00173.2006","volume":"292","author":"SR Baber","year":"2007","unstructured":"Baber, S. R. et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H1120\u2013H1128 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1191_CR116","doi-asserted-by":"crossref","first-page":"L315","DOI":"10.1152\/ajplung.00089.2009","volume":"298","author":"V Balasubramaniam","year":"2010","unstructured":"Balasubramaniam, V. et al. Bone marrow-derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am. J. Physiol. Lung Cell Mol. Physiol. 298, L315\u2013L323 (2010).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1191_CR117","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jpedsurg.2014.01.013","volume":"49","author":"J Di Bernardo","year":"2014","unstructured":"Di Bernardo, J., Maiden, M. M., Hershenson, M. B. & Kunisaki, S. M. Amniotic fluid derived mesenchymal stromal cells augment fetal lung growth in a nitrofen explant model. J. Pediatr. Surg. 49, 859\u2013864 (2014).","journal-title":"J. Pediatr. Surg."},{"key":"1191_CR118","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/pr.2017.232","volume":"83","author":"M Kang","year":"2018","unstructured":"Kang, M. & Thebaud, B. Stem cell biology and regenerative medicine for neonatal lung diseases. Pediatr. Res. 83, 291\u2013297 (2018).","journal-title":"Pediatr. Res."},{"key":"1191_CR119","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00383-014-3576-9","volume":"30","author":"R Yuniartha","year":"2014","unstructured":"Yuniartha, R. et al. Therapeutic potential of mesenchymal stem cell transplantation in a nitrofen-induced congenital diaphragmatic hernia rat model. Pediatr. Surg. Int. 30, 907\u2013914 (2014).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR120","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00383-019-04561-7","volume":"35","author":"S Takayama","year":"2019","unstructured":"Takayama, S. et al. An intra-amniotic injection of mesenchymal stem cells promotes lung maturity in a rat congenital diaphragmatic hernia model. Pediatr. Surg. Int. 35, 1353\u20131361 (2019).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR121","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3727\/096368912X657756","volume":"22","author":"F Pederiva","year":"2013","unstructured":"Pederiva, F. et al. Amniotic fluid stem cells rescue both in vitro and in vivo growth, innervation, and motility in nitrofen-exposed hypoplastic rat lungs through paracrine effects. Cell Transplant. 22, 1683\u20131694 (2013).","journal-title":"Cell Transplant."},{"key":"1191_CR122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.placenta.2017.05.010","volume":"59","author":"M Vanover","year":"2017","unstructured":"Vanover, M., Wang, A. & Farmer, D. Potential clinical applications of placental stem cells for use in fetal therapy of birth defects. Placenta 59, 107\u2013112 (2017).","journal-title":"Placenta"},{"key":"1191_CR123","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mvr.2009.02.001","volume":"77","author":"D Furlani","year":"2009","unstructured":"Furlani, D. et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc. Res. 77, 370\u2013376 (2009).","journal-title":"Microvasc. Res."},{"key":"1191_CR124","doi-asserted-by":"crossref","unstructured":"Yeung, V. et al. Paving the road for mesenchymal stem cell-derived exosome therapy in bronchopulmonary dysplasia and pulmonary hypertension. Stem Cell Based Therapy Lung Dis. 131\u2013152 (2019).","DOI":"10.1007\/978-3-030-29403-8_8"},{"key":"1191_CR125","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41419-018-1073-0","volume":"9","author":"M Zhang","year":"2018","unstructured":"Zhang, M. et al. Exosomal 15-LO2 mediates hypoxia-induced pulmonary artery hypertension in vivo and in vitro. Cell Death Dis. 9, 1022 (2018).","journal-title":"Cell Death Dis."},{"key":"1191_CR126","volume":"21","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. Mesenchymal stromal cell-derived exosomes improve pulmonary hypertension through inhibition of pulmonary vascular remodeling. Respiratory Res. 21, 71 (2020).","journal-title":"Respiratory Res."},{"key":"1191_CR127","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-1","volume":"7","author":"JA Tovar","year":"2012","unstructured":"Tovar, J. A. Congenital diaphragmatic hernia. Orphanet J. Rare Dis. 7, 1 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"1191_CR128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00383-013-3340-6","volume":"29","author":"M Makanga","year":"2013","unstructured":"Makanga, M. et al. Downregulated bone morphogenetic protein signaling in nitrofen-induced congenital diaphragmatic hernia. Pediatr. Surg. Int. 29, 823\u2013834 (2013).","journal-title":"Pediatr. Surg. Int."},{"key":"1191_CR129","first-page":"577","volume":"80","author":"CM Burgos","year":"2016","unstructured":"Burgos, C. M. et al. Improved pulmonary function in the nitrofen model of congenital diaphragmatic hernia following prenatal maternal dexamethasone and\/or sildenafil. Pediatr. Surg. 80, 577\u2013585 (2016).","journal-title":"Pediatr. Surg"},{"key":"1191_CR130","doi-asserted-by":"crossref","first-page":"263.e1","DOI":"10.1016\/j.ajog.2014.03.013","volume":"211","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto, Y., Thebaud, B., Vadivel, A., Eaton, F., Jain, V., Hornberger, L. K., Doppler parameters of fetal lung hypoplasia and impact of\u00a0sildenafil. Am J Obstet Gynecol. 211, 263.e1\u2013263.e8 (2014).","journal-title":"Am J Obstet Gynecol"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-01191-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-01191-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-01191-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T18:35:42Z","timestamp":1633890942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-01191-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":130,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1038\/s41390-020-01191-x","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}